| Company Name: |
T&W GROUP |
| Tel: |
021-61551611 13296011611 |
| Email: |
contact@trustwe.com |
- BioE-1115
-
- $30.00
-
2026-07-14
- CAS:1268863-35-9
- Purity: 97.54%
- Supply Ability: 10g
- BioE-1115
-
- $30.00
-
2026-07-14
- CAS:1268863-35-9
- Purity: 97.54%
- Supply Ability: 10g
|
| | 2-(4-fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid Basic information |
| Product Name: | 2-(4-fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid | | Synonyms: | 2-(4-fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid;6-Quinoxalinecarboxylic acid, 2-(4-fluorophenyl)-3-[methyl(1-methylethyl)amino]-;BioE1115;BIOE-1115;BioE 1115,Threonine proteases,Ser/Thr Protease,Inhibitor,BioE1115,inhibit,Serine proteases,Serine endopeptidases,BioE-1115,Casein Kinase;BioE-1115, 10 mM in DMSO;PAS Kinase Inhibitor, BioE-1115;BioE-1115 ，S0995 | | CAS: | 1268863-35-9 | | MF: | C19H18FN3O2 | | MW: | 339.3635232 | | EINECS: | | | Product Categories: | | | Mol File: | 1268863-35-9.mol |  |
| | 2-(4-fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMSO: 50mg/mL | | form | Solid | | color | Light yellow to yellow |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | 2-(4-fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid Usage And Synthesis |
| Uses | BioE-1115 is a highly selective and potent PAS kinase (PASK) inhibitor with an IC50 of ~4 nM. BioE-1115 is also a potent casein kinase 2α inhibitor with an IC50 of ~10 μM[1]. | | Biological Activity | Cell permeable: yes', 'Primary Target
PASK | | in vivo | BioE-1115 (1-100 mg/kg; oral gavage; daily; for 7 days; male Sprague-Dawley rats) treatment shows a dose-dependent suppression of the expression of Gpat1, Fasn and all other SREBP-1c target genes analyzed. SREBP-1 maturation in liver is also suppressed in BioE-1115 treated rats at 10, 30 and 100 mg/kg doses. A calculated measure of insulin resistance, HOMA-IR, is decreased in a dose-dependent manner by BioE-1115 administration. Hepatic and serum TAG are decreased in a dose-dependent manner by BioE-1115 administration. BioE-1115 treatment causes a significant decrease in serum glucose. Both SREBP-1c and SREBP-1a mRNA are modestly decreased at the highest doses. Neither dose of BioE-1115 causes a significant change in either liver weight or body weight[1]. | Animal Model: | Male Sprague-Dawley rats (12 weeks of age; 129.4 ± 0.63 g) fed with high fructose diet[1] | | Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg and 100 mg/kg | | Administration: | Oral gavage; daily; for 7 days | | Result: | Treated with 10, 30 and 100 mg/kg, showed a dose-dependent suppression of the expression of Gpat1, Fasn and all other SREBP-1c target genes analyzed. Decreased hepatic expression of lipogenic SREBP-1c target genes, decreased serum triglycerides and partially reversed insulin resistance.
|
| | IC 50 | CK2α: 10 μM (IC50) | | References | [1] Wu X, et al. PAS kinase drives lipogenesis through SREBP-1 maturation. Cell Rep. 2014 Jul 10;8(1):242-55. DOI:10.1016/j.celrep.2014.06.006 |
| | 2-(4-fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid Preparation Products And Raw materials |
|